Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for marketing & advertising industry professionals · Thursday, March 28, 2024 · 699,409,286 Articles · 3+ Million Readers

IntelGenx Engages Focus Communications for Investor Relations Program

SAINT LAURENT, Quebec, Nov. 30, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announce the engagement of Focus Communications (“Focus”) to provide online marketing and corporate communications services to the Company.  Focus has been retained on a twelve month contract basis to advise the Company with respect to its online marketing endeavours and assisting management in developing a strategy to help expand and support corporate development initiatives. Focus will also assist IntelGenx in increasing investor awareness by managing the Company’s corporate communications, marketing undertakings, ongoing engagement with shareholders, finance professionals and media contacts.

Under the terms of the agreement, IntelGenx will pay Focus Communications C$5,000 per month for an initial twelve month term and grant 100,000 stock options at an exercise price of US$0.81.

About Focus Communications

Focus Communications is a private Toronto based firm providing investor relations, corporate communications and market awareness services. Focus implements a proactive and “one on one” approach in managing relationships between clients, their shareholders and the investment community while specializing in executing strategic marketing initiatives that enhance liquidity and create greater visibility within the capital markets.

About IntelGenx

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx’s state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information is available about the Company at: www.intelgenx.com.

Forward-Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.  Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source:  IntelGenx Technologies Corp.

For more information, please contact:
                    
                    Stephen Kilmer
                    Investor Relations 
                    (514) 331-7440 ext 232
                    stephen@intelgenx.com
                    
                    Or
                    
                    Andre Godin, CPA, CA
                    Executive Vice-President and CFO
                    IntelGenx Corp.
                    (514) 331-7440 ext 203
                    andre@intelgenx.com

IGX Logo Medium Size.jpg

Powered by EIN News
Distribution channels: Healthcare & Pharmaceuticals Industry


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release